Advertisement

Adjuvant Endocrine Therapy

  • Harold J. Burstein
Chapter

Abstract

Adjuvant endocrine therapy is a mainstay of treatment for women with hormone-receptor (estrogen-receptor and/or progesterone-receptor) expressing breast cancers. Extensive clinical trials over decades have demonstrated compelling improvements in overall survival and disease-free survival with use of adjuvant endocrine therapy. Along with implementation of widespread screening mammography programs, use of adjuvant endocrine therapy has contributed substantially to the decline in breast cancer mortality seen in the US and other developed societies. Around the world, it is likely that adjuvant endocrine treatment has contributed more to the reduction in cancer mortality than any other therapy employed in medical oncology. This chapter provides an overview of current adjuvant endocrine approaches to breast cancer therapy.

Keywords

Breast Cancer Premenopausal Woman Aromatase Inhibitor Adjuvant Endocrine Therapy Tamoxifen Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Early Breast Cancer Trialists’ Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRefGoogle Scholar
  2. 2.
    Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93(9):684–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Peto R, Davies C; on Behalf of the ATLAS Collaboration. ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 2010,500 women preliminary results. In: 30th Annual San Antonio Breast Cancer Symposium; 2007:abstract 48. Available at www.sabcs.org.
  4. 4.
    Gray RG, Rea DW, Handley K, Marshall A, Pritchard G, Perry P, et al. aTTom (adjuvant Tamoxifen–To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer–preliminary results. Proc ASCO; 2008:abstract 513. Available at: www.asco.org.
  5. 5.
    Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19(4):931–42.Google Scholar
  6. 6.
    Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003;21(3): 453–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27): 2817–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ET-positive breast cancer. in: 27th Annual San Antonio Breast Cancer Supplement Symposium; 2004:abstract 37. Breast Cancer Research and Treatment 2007; S8814,INT0100.Google Scholar
  9. 9.
    Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14(10):2731–7.PubMedGoogle Scholar
  10. 10.
    Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(2010):937–47.PubMedCrossRefGoogle Scholar
  11. 2010.
    Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):20103–21.CrossRefGoogle Scholar
  13. 13.
    Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Dellapasqua S, Colleoni M, Gelder RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005;23(8):1736–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Parton M, Smith IE. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol. 2008;26(5):745–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17(10):1497–503.PubMedCrossRefGoogle Scholar
  17. 17.
    Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn JH. 10th St Gallen Conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):201033–44.CrossRefGoogle Scholar
  18. 18.
    Anon. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1996;348(9036):201089–96.Google Scholar
  19. 19.
    International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003;95(24):1833–46.Google Scholar
  20. 20.
    LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):172010–23.Google Scholar
  21. 21.
    Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005;23(25):5973–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24(36):5769–79.PubMedCrossRefGoogle Scholar
  23. 23.
    International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006;24(9):1332–41.Google Scholar
  24. 24.
    Burstein HJ, Mayer E, Patridge AH, O’Kane H, Litsas G, Come SE, et al. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006;7(2):158–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive stage I and II breast cancer : First efficacy results from ABCSG-12. J Clin Oncol 2008;26(suppl):abstract LBA4.Google Scholar
  27. 27.
    Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008;26(5):798–805.PubMedCrossRefGoogle Scholar
  28. 28.
    Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22:4261–71.PubMedCrossRefGoogle Scholar
  30. 30.
    Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23:6931–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:20109–27.CrossRefGoogle Scholar
  33. 33.
    Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–36.PubMedCrossRefGoogle Scholar
  34. 34.
    Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–57.PubMedCrossRefGoogle Scholar
  35. 35.
    Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25:3797–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25:3877–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26:5569–75.PubMedCrossRefGoogle Scholar
  39. 39.
    Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005;23:5178–87.PubMedCrossRefGoogle Scholar
  40. 40.
    Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer. J Clin Oncol 2010;28:3784–96.PubMedCrossRefGoogle Scholar
  41. 41.
    BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776.Google Scholar
  42. 42.
    Rea D, Hasenburg A, Seynaeve C, et al. Presented at the 32nd Annual San Antonio Breast Cancer Symposium (December 9-13, 2009, San Antonio, TX), Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM Trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer).Google Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  1. 1.Harvard Medical SchoolDana-Farber Cancer InstituteBostonUSA

Personalised recommendations